Human adipose derived mesenchymal stem cell extracellular vesicles ameliorate ovarian BMP15 and GDF9 expression in premature ovarian insufficiency mice
Abstract Premature ovarian insufficiency (POI) is a major cause of infertility and long-term health complications in young women and can result from gonadotoxic chemotherapy. Current management alleviates symptoms but does not restore ovarian reserve. Human adipose-derived mesenchymal stem cell-derived extracellular vesicles (hAD-MSC-EVs) have shown therapeutic potential in preclinical POI models. Human adipose-derived mesenchymal stem cells (hAD-MSCs) were expanded and characterized by morphology and flow cytometric immunophenotyping. Extracellular vesicles (EVs) were isolated from conditioned medium by sequential centrifugation and ultracentrifugation and characterized using dynamic light scattering, transmission electron microscopy, the Bradford assay, and Western blotting for CD63, TSG101, and calnexin. POI was induced in mice using cyclophosphamide and busulfan. Animals received hAD-MSC-EVs via tail vein injection. Serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) levels were measured, and ovarian histology was evaluated using hematoxylin and eosin staining. Ovarian messenger RNA (mRNA) levels of Bmp15 , Gdf9 , Foxo3 , and Mapk3 , encoding bone morphogenetic protein 15 (BMP15), growth differentiation factor 9 (GDF9), forkhead box O3, and mitogen-activated protein kinase 3, respectively, were quantified, together with ovarian BMP15 and GDF9 protein levels. EV treatment partially ameliorated POI-associated endocrine alterations, reducing FSH and increasing LH and E2 levels compared with untreated POI mice. Histological analysis showed improved ovarian architecture and reduced stromal abnormalities. Ovarian BMP15 and GDF9 protein levels were higher in EV-treated mice than in untreated POI mice and did not differ significantly from control levels. However, Bmp15 and Gdf9 mRNA levels increased only modestly and remained below control levels, whereas Foxo3 and Mapk3 mRNA levels did not differ significantly among groups. hAD-MSC-EV treatment was associated with partial endocrine and histological improvement and increased ovarian BMP15 and GDF9 protein levels in mice with chemotherapy-induced POI. These findings support further investigation of hAD-MSC-EVs as a potential approach to ovarian recovery, while the mechanisms underlying these associations remain to be established.
Authors
- Fateme Arjmand (ORCID: https://orcid.org/0000-0001-5650-4783)
- Jamileh Sadat Mirsanei (ORCID: https://orcid.org/0000-0002-7312-3701)
- Mehdi Mehdizadeh (ORCID: https://orcid.org/0000-0002-2673-2715)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1038/s41598-026-79916-x
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00